Physician, recognized scientist and executive, Dr Hofmann brings over 25 years international experience and long-standing relationships with worldwide opinion leaders in pulmonary diseases. Most recently Chief Scientific Officer of MannKind Corporation, following the acquisition of Qrumpharma, a pharmaceutical company founded by Dr Hofmann. Previously, Dr Hofmann held multiple executive positions in the pharmaceutical industry, Aumapharma LLC, Activaero GmbH, Discovery Labs, Corus Pharma, and Pulmopharm. 

While at MannKind/Qrumpharma, Dr Hofmann led the successful developed of nhaled Clofazimine suspension for the management of Nontuberculous Mycobacteria, currently in preparation for a registration trial. He also led the development and of inhaled corticosteroids Akita and Favolir for asthma (approved, Activaero GmbH), and aztreonam for inhalation (Cayston, Gilead). Dr Hofmann has substantial entrepreneurial experience, completing three startup developments and exits (Qrumpharma, Activaero, and Corus).

Appointed Adjunct Professor at Temple University (Department of Biomedical Engineering), he is the holder of numerous patents related to pulmonary diseases therapies and widely published in medical journals on the subject of treatment of lung diseases, Dr Hofmann is a recipient of the Milton Graub Clinical Achievement Award from the U.S. Cystic Fibrosis Foundation.